Research Analysts Issue Forecasts for CATX Q1 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Research analysts at Wedbush raised their Q1 2025 earnings per share estimates for Perspective Therapeutics in a note issued to investors on Wednesday, March 26th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.31) per share for the quarter, up from their previous estimate of ($0.37). Wedbush has a “Outperform” rating and a $11.00 price objective on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Wedbush also issued estimates for Perspective Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($1.63) EPS and FY2027 earnings at ($1.73) EPS.

CATX has been the subject of a number of other research reports. Royal Bank of Canada cut their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Finally, Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. One analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $14.44.

Perspective Therapeutics Stock Down 4.3 %

Shares of CATX stock opened at $2.20 on Monday. The stock has a fifty day moving average price of $2.94 and a 200 day moving average price of $6.29. Perspective Therapeutics has a 1 year low of $2.19 and a 1 year high of $19.05.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Intech Investment Management LLC acquired a new stake in shares of Perspective Therapeutics during the third quarter worth $137,000. Charles Schwab Investment Management Inc. grew its position in shares of Perspective Therapeutics by 221.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after buying an additional 298,778 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Perspective Therapeutics by 8.9% during the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock worth $274,000 after acquiring an additional 1,672 shares during the period. FMR LLC lifted its holdings in Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after acquiring an additional 5,370,392 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Perspective Therapeutics by 1,302.7% in the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after acquiring an additional 44,174 shares during the period. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.